-
公开(公告)号：EP2862855A1
公开(公告)日：2015-04-22
申请号：EP13804194.2
申请日：2013-06-13
发明人： ARAKI Yuko , NOZAWA Dai , SUZUKI Ryo , OHTA Hiroshi , FUTAMURA Aya , ABE Masahito , AMADA Hideaki , KONISHI Kazuhide , OGATA Yuya
IPC分类号： C07D249/06 , A61K31/4439 , A61K31/506 , A61P1/00 , A61P5/00 , A61P9/12 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P29/00 , A61P37/02 , C07D401/14
CPC分类号： C07D413/14 , A61K31/4192 , A61K31/4245 , A61K31/4439 , A61K31/444 , A61K31/506 , C07D249/06 , C07D401/14 , C07D403/12 , C07D413/12
摘要： A branched chain alkyl heteroaromatic ring derivative represented by formula (Ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of the orexin (OX) receptor antagonist activity.
摘要翻译： 由式（Ia）表示的支链烷基杂芳族环衍生物或其药学上可接受的盐可用于治疗或预防睡眠障碍，抑郁症，焦虑障碍，恐慌症，精神分裂症，药物依赖，阿尔茨海默氏病，帕金森病 根据食欲素（OX）受体拮抗剂活性，亨廷顿病，饮食失调，头痛，焦虑，疼痛，消化系统疾病，癫痫，炎症，免疫相关疾病，内分泌相关疾病和高血压。
-
2.发明授权1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS 有权1,3-恶唑烷或1.3恶嗪化合物作为食欲素受体拮抗剂
公开(公告)号：EP2862860B1
公开(公告)日：2016-12-21
申请号：EP13804876.4
申请日：2013-06-13
发明人： FUTAMURA Aya , ARAKI Yuko , ABE Masahito , OHTA Hiroshi , SUZUKI Ryo , NOZAWA Dai
IPC分类号： C07D413/14 , A61K31/4439 , A61K31/5355 , A61P1/04 , A61P1/14 , A61P3/00 , A61P9/12 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P29/00 , A61P37/02
CPC分类号： C07D413/14
-
公开(公告)号：EP2599775A1
公开(公告)日：2013-06-05
申请号：EP11812613.5
申请日：2011-07-29
发明人： NAKAMURA Toshio , SAKAGAMI Kazunari , KONISHI Kazuhide , YAMAMOTO Kanako , MASUDA Seiji , MATSUDA Yohei , OKADA Kumiko , SHIBATA Tsuyoshi , OHTA Hiroshi , YASUHARA Akito , KAWAMOTO Hiroshi
IPC分类号： C07D231/12 , A61K31/415 , A61K31/4155 , A61K31/417 , A61K31/4174 , A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/506 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D231/14
CPC分类号： C07D231/12 , C07D231/14 , C07D231/20 , C07D231/38 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/06 , C07D413/04
摘要： Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.
摘要翻译： 提供了式II所示的新型化合物或其药学上可接受的盐，其对II型代谢型谷氨酸（m-Glu）受体具有拮抗活性。 该化合物或其药学上可接受的盐可用作新型心境障碍（抑郁症和双相性精神障碍），焦虑症（广泛性焦虑症，恐慌症，强迫症，社交焦虑症， 创伤应激障碍，特定恐怖症和急性应激障碍），精神分裂症，阿尔茨海默病，认知功能障碍，痴呆，药物依赖性，惊厥，震颤，疼痛，睡眠障碍等。
-
4.发明公开HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE 有权1,3-OXAZOLIDIN-ODER 1,3-OXAZINAN-VERBINDUNGEN ALS OREXIN REZEPTOR ANTAGONISTEN
公开(公告)号：EP2862860A1
公开(公告)日：2015-04-22
申请号：EP13804876.4
申请日：2013-06-13
发明人： FUTAMURA Aya , ARAKI Yuko , ABE Masahito , OHTA Hiroshi , SUZUKI Ryo , NOZAWA Dai
IPC分类号： C07D413/14 , A61K31/4439 , A61K31/5355 , A61P1/04 , A61P1/14 , A61P3/00 , A61P9/12 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P29/00 , A61P37/02
CPC分类号： C07D413/14
摘要： A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity.
摘要翻译： 由式（IA）表示的杂芳基甲基环胺衍生物或其药学上可接受的盐可用于治疗或预防睡眠障碍，抑郁症，焦虑障碍，恐慌症，精神分裂症，药物依赖，阿尔茨海默氏病，帕金森氏病， 基于食欲素（OX）受体拮抗剂活性，亨廷顿氏病，饮食失调，头痛，血尿，疼痛，消化系统疾病，癫痫，炎症，免疫相关疾病，内分泌相关疾病和高血压。
-
公开(公告)号：EP2708537A1
公开(公告)日：2014-03-19
申请号：EP12781685.8
申请日：2012-05-08
发明人： SUZUKI Ryo , FUTAMURA Aya , ABE Masahito , KASHIWA Shuhei , HATTORI Nobutaka , NOZAWA Dai , OHTA Hiroshi , ARAKI Yuko
IPC分类号： C07D401/14 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/4439 , A61K31/506 , A61P1/00 , A61P5/00 , A61P9/12 , A61P25/08 , A61P25/16 , A61P25/20 , A61P25/22 , A61P25/24
CPC分类号： C07D413/14 , C07D401/14 , C07D403/12 , C07D413/12
摘要： The compound represented by formula (IA)
or a pharmaceutically acceptable salt thereof is based on orexin (OX) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.摘要翻译： 由式（IA）表示的化合物或其药学上可接受的盐是基于食欲肽（OX）受体拮抗剂活性，可用于治疗和预防包括睡眠障碍，抑郁症，焦虑障碍，恐慌症，精神分裂症，药物依赖性 ，阿尔茨海默病，帕金森病，亨廷顿舞蹈病，进食障碍，疼痛，胃肠道疾病，癫痫，炎症，免疫疾病，内分泌相关疾病和高血压。
-
公开(公告)号：EP2604602A1
公开(公告)日：2013-06-19
申请号：EP11816483.9
申请日：2011-08-11
发明人： NAKAMURA Toshio , SAKAGAMI Kazunari , KONISHI Kazuhide , YAMAMOTO Kanako , MASUDA Seiji , MATSUDA Yohei , OKADA Kumiko , SHIBATA Tsuyoshi , OHTA Hiroshi , YASUHARA Akito , KAWAMOTO Hiroshi , AMADA Hideaki , URABE Hiroki , NISHIKAWA Rie , KASHIWA Shuhei
IPC分类号： C07D403/04 , A61K31/4155 , A61K31/4245 , A61K31/4439 , A61P25/04 , A61P25/08 , A61P25/20 , A61P25/22 , A61P25/28 , A61P25/36 , C07D403/14 , C07D413/04 , C07D413/14
CPC分类号： C07D413/14 , C07D231/38 , C07D403/04 , C07D403/14 , C07D413/04
摘要： A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a phamaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.
摘要翻译： 由式[I]表示的化合物和所述化合物的药学上可接受的盐是对II类代谢型谷氨酸（mGlu）受体发挥拮抗活性的新化合物及其药学上可接受的盐，并且作为新型预防剂或治疗剂 （抑郁症，双相性精神障碍等），焦虑症（广泛性焦虑症，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特定的恐怖症，急性应激障碍等） ），精神分裂症，阿尔茨海默病，认知障碍，痴呆，药物依赖，惊厥，寒战，疼痛，睡眠障碍等。
-
公开(公告)号：EP2653469A1
公开(公告)日：2013-10-23
申请号：EP11848589.5
申请日：2011-12-16
发明人： NOZAWA Dai , SUZUKI Ryo , FUTAMURA Aya , SHIMONO Rie , ABE Masahito , OHTA Hiroshi , ARAKI Yuko
IPC分类号： C07D401/14 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/506 , A61P1/00 , A61P1/14 , A61P5/00 , A61P9/12 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P29/00
CPC分类号： A61K31/4192 , A61K31/4439 , A61K31/506 , C07D401/14 , C07D403/12 , C07D405/14
摘要： A compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for the treatment or prevention of diseases such sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, pain, gastrointestinal diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases, and hypertension, and of which the action relies on an orexin (OX) receptor antagonistic activity.
摘要翻译： 由式（IA）表示的化合物或其药学上可接受的盐，其可用于治疗或预防睡眠障碍，抑郁症，焦虑障碍，恐慌症，精神分裂症，药物依赖性，阿尔茨海默氏病，帕金森病，亨廷顿舞蹈病 ，饮食失调，疼痛，胃肠疾病，癫痫，炎症，免疫相关疾病，内分泌相关疾病和高血压，其作用依赖于食欲肽（OX）受体拮抗作用。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
